Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jennifer C. Bare"'
Autor:
Cheryl A Stoddart, Pheroze Joshi, Barbara Sloan, Jennifer C Bare, Philip C Smith, Graham P Allaway, Carl T Wild, David E Martin
Publikováno v:
PLoS ONE, Vol 2, Iss 11, p e1251 (2007)
The HIV-1 maturation inhibitor, 3-O-(3',3'-dimethylsuccinyl) betulinic acid (bevirimat, PA-457) is a promising drug candidate with 10 nM in vitro antiviral activity against multiple wild-type (WT) and drug-resistant HIV-1 isolates. Bevirimat has a no
Externí odkaz:
https://doaj.org/article/767cee83f8bd4f77a00802dac5c2710b
Autor:
Cheryl A Stoddart, Cheryl A Bales, Jennifer C Bare, George Chkhenkeli, Sofiya A Galkina, April N Kinkade, Mary E Moreno, José M Rivera, Rollie E Ronquillo, Barbara Sloan, Paul L Black
Publikováno v:
PLoS ONE, Vol 2, Iss 7, p e655 (2007)
The SCID-hu Thy/Liv mouse model of HIV-1 infection is a useful platform for the preclinical evaluation of antiviral efficacy in vivo. We performed this study to validate the model with representatives of all four classes of licensed antiretrovirals.E
Externí odkaz:
https://doaj.org/article/fb047b72aca54c4094161004657b21ea
Autor:
Pheroze Joshi, Carl T. Wild, Philip C. Smith, David E. Martin, Barbara Sloan, Jennifer C. Bare, Graham P. Allaway, Cheryl A. Stoddart
Publikováno v:
PLoS ONE
PLoS ONE, Vol 2, Iss 11, p e1251 (2007)
PLoS ONE, Vol 2, Iss 11, p e1251 (2007)
Background The HIV-1 maturation inhibitor, 3-O-(3′,3′-dimethylsuccinyl) betulinic acid (bevirimat, PA-457) is a promising drug candidate with 10 nM in vitro antiviral activity against multiple wild-type (WT) and drug-resistant HIV-1 isolates. Bev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::662f4e18cd94a43147a9bf7c1355a649
http://europepmc.org/articles/PMC2080775
http://europepmc.org/articles/PMC2080775
Autor:
Barbara Sloan, Jose M. Rivera, Cheryl A. Bales, Mary E. Moreno, April N. Kinkade, Sofiya A. Galkina, Cheryl A. Stoddart, Rollie Ronquillo, George Chkhenkeli, Paul L. Black, Jennifer C. Bare
Publikováno v:
PLoS ONE, Vol 2, Iss 7, p e655 (2007)
PloS one, vol 2, iss 7
PLoS ONE
PloS one, vol 2, iss 7
PLoS ONE
Background The SCID-hu Thy/Liv mouse model of HIV-1 infection is a useful platform for the preclinical evaluation of antiviral efficacy in vivo. We performed this study to validate the model with representatives of all four classes of licensed antire
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e06c94bf160cab2dad670e3d59dd1835
http://europepmc.org/articles/PMC1925140?pdf=render
http://europepmc.org/articles/PMC1925140?pdf=render